Evidence map›Paper›PMID 32511100›Full record

ArticleJMIR public health and surveillance2020

Distribution of Patients at Risk for Complications Related to COVID-19 in the United States: Model Development Study.

Renae Smith-Ray, Erin E Roberts, Devonee E Littleton, Tanya Singh, Thomas Sandberg, Michael Taitel

Abstract read
In one paragraph

Article in JMIR public health and surveillance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Renae Smith-RayWalgreens Center for Health and Wellbeing Research, Health Analytics, Research, and Reporting, Walgreen Co, Deerfield, IL, United States.ORCID 0000-0001-9642-7727
Erin E RobertsWalgreens Center for Health and Wellbeing Research, Health Analytics, Research, and Reporting, Walgreen Co, Deerfield, IL, United States.ORCID 0000-0002-9169-9456
Devonee E LittletonHealthcare Planning and Research, Walgreen Co, Deerfield, IL, United States.ORCID 0000-0001-5167-0475
Tanya SinghWalgreens Center for Health and Wellbeing Research, Health Analytics, Research, and Reporting, Walgreen Co, Deerfield, IL, United States.ORCID 0000-0001-8608-138X
Thomas SandbergHealthcare Planning and Research, Walgreen Co, Deerfield, IL, United States.ORCID 0000-0003-1682-674X
Michael TaitelWalgreens Center for Health and Wellbeing Research, Health Analytics, Research, and Reporting, Walgreen Co, Deerfield, IL, United States.ORCID 0000-0002-3582-4451

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease (COVID-19) has spread exponentially across the United States. Older adults with underlying health conditions are at an especially high risk of developing life-threatening complications if infected. Most intensive care unit (ICU) admissions and non-ICU hospitalizations have been among patients with at least one underlying health condition.

objectiveThe aim of this study was to develop a model to estimate the risk status of the patients of a nationwide pharmacy chain in the United States, and to identify the geographic distribution of patients who have the highest risk of severe COVID-19 complications.

methodsA risk model was developed using a training test split approach to identify patients who are at high risk of developing serious complications from COVID-19. Adult patients (aged ≥18 years) were identified from the Walgreens pharmacy electronic data warehouse. Patients were considered eligible to contribute data to the model if they had at least one prescription filled at a Walgreens location between October 27, 2019, and March 25, 2020. Risk parameters included age, whether the patient is being treated for a serious or chronic condition, and urban density classification. Parameters were differentially weighted based on their association with severe complications, as reported in earlier cases. An at-risk rate per 1000 people was calculated at the county level, and ArcMap was used to depict the rate of patients at high risk for severe complications from COVID-19. Real-time COVID-19 cases captured by the Johns Hopkins University Center for Systems Science and Engineering (CSSE) were layered in the risk map to show where cases exist relative to the high-risk populations.

resultsOf the 30,100,826 adults included in this study, the average age is 50 years, 15% have at least one specialty medication, and the average patient has 2 to 3 comorbidities. Nearly 28% of patients have the greatest risk score, and an additional 34.64% of patients are considered high-risk, with scores ranging from 8 to 10. Age accounts for 53% of a patient's total risk, followed by the number of comorbidities (29%); inferred chronic obstructive pulmonary disease, hypertension, or diabetes (15%); and urban density classification (5%).

conclusionsThis risk model utilizes data from approximately 10% of the US population. Currently, this is the most comprehensive US model to estimate and depict the county-level prognosis of COVID-19 infection. This study shows that there are counties across the United States whose residents are at high risk of developing severe complications from COVID-19. Our county-level risk estimates may be used alongside other data sets to improve the accuracy of anticipated health care resource needs. The interactive map can also aid in proactive planning and preparations among employers that are deemed critical, such as pharmacies and grocery stores, to prevent the spread of COVID-19 within their facilities.

Indexed as

AdolescentAdultAgedAged, 80 and overChronic DiseaseComorbidityCoronavirus InfectionsCOVID-19HumansMiddle AgedModels, TheoreticalPandemicsPneumonia, ViralPrognosisRisk AssessmentRisk Factorschronic conditionsCOVID-19modelingolder adults

Identifiers

PMID32511100
PMCPMC7304254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.